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Abstract The antibiotic kirromycin inhibits protein synthesis by binding to EF-Tu and preventing its release from the ribosome after GTP hydrolysis. 
We have isolated and sequenced a collection of kirromycin resistant uf mutations and identified thirteen single amino acid substitutions at seven 
different sites in EF-Tu. These have been mapped onto the 3D structures of EF-Tu’GTP and EF-Tu.GDP. In the active GTP form of EF-Tu the 
mutations cluster on each side of the interface between domains I and III. We propose that this domain interface is the binding site for kirromycin. 
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1. Introduction 
EF-Tu is an essential component of bacterial protein biosyn- 
thesis and forms a ternary complex with GTP and aminoacyl- 
tRNA [l]. This complex interacts with the elongating ribosome, 
placing aminoacyl-tRNA in the A-site. After codon-anticodon 
interaction, GTP on EF-Tu is hydrolysed, causing the dissocia- 
tion of EF-Tu. GDP from aa-tRNA and from the ribosome. 
EF-Tu.GDP is subsequently recycled to an active form 
via a nucleotide exchange reaction promoted by EF-Ts, after 
which it can again form a ternary complex with aa-tRNA [2]. 
High resolution crystallographic structures of EF-Tu in its 
GDP and GTP conformations have recently been solved [3-51. 
Kirromycin is an antibiotic of MW 797 which affects protein 
synthesis by binding to EF-Tu and inhibiting the release of 
EF-Tu.GDP from the ribosome, thus preventing elonga- 
tion from progressing [6]. Kirromycin is known from in vitro 
studies to interact with both the EF-Tu.GDP and EF-Tu.GTP 
forms of the factor. 
Several mutants resistant o kirromycin have previously been 
isolated in Salmonella typhimurium and Escherichia coli. Most 
mutations causing kirromycin resistance map in the genes for 
EF-Tu, tufA and t&B [7,8], and sequence alterations causing 
five changes at four positions have been identified and reported 
[9-121. Mutations causing kirromycin resistance have also been 
identified in rpsL, as error restrictive mutants of ribosomal 
protein S12 [13]. In an attempt o define the kirromycin binding 
region of EF-Tu we have isolated a large number of spontane- 
ous kirromycin resistant mutants, identified the sequence alter- 
ations, and mapped these residues, and those of the previously 
identified mutants, onto the 3D structures of EF-Tu [3,4]. The 
kirromycin resistant mutations are caused individually by thir- 
teen amino acid substitutions at seven different residues, and 
one amino acid deletion at another site. The mutations map in 
the structural domains I and III. All of the amino acid substi- 
tutions are in the domain I-III interface when EF-Tu is in the 
GTP conformation, but are dispersed when EF-Tu is in its 
GDP conformation. The deletion maps in the loop connecting 
domains II and III. 
*Corresponding author. Fax: (46) (18) 557 723. 
2. Materials and methods 
2.1. Selection and identification of mutations 
Kirromycin resistant mutants were selected spontaneously on LC 
media [7] containing 2 mM EDTA (pH 8.0) and 100 &ml kirromycin 
at 30°C with S. typhimurium. The strains used for most of the selections 
carried onlv one active tuf eene (TH381. rroE91 tufA300:: MudJ: and 
TH701, triE91 tufB4.41:: h;udJ~ but one ‘mutation was selected in 
TH488 (trpE91 hisG3720 tufA8). Mutations causing resistance to kirro- 
mycin were mapped by transduction and the relevant tuf gene se- 
quenced after asymmetric PCR amplification. 
2.2. PCR and sequencing 
The PCR oligos and amplification protocols were as described previ- 
ously [1 l] with the following modifications. DNA for PCR amplifica- 
tion was prepared by suspending a bacterial colony in 50 ~1 distilled 
water in a microfuge tube, incubating for 30 min at 37°C (the cells 
swell), adding 5 ~1 of this solution to a standard PCR buffer and primer 
mixture and subjecting this to PCR (the swollen cells burst and release 
their DNA). The DNA oligos used for tufA amplification were Sal3’ 
(+42 to +20 nt downstream of tufA, SCCGAAGCGCCCTCTTCA- 
ATTCAAA3’); 5’ efg-end (the last eight codons in fusA plus the 
termination triplet [14], 5’GCCGTAATTGAAGCCCGTGGTAAAT- 
AA3’); and TAS (-54 to -30 upstream of tufA [14], S’CCAAAATC- 
CCGTGCTCTCTCCTGAA3’). The Sa13’ sequence information was 
obtained by inverse PCR and sequencing of the region immediately 
downstream of tufA in S. typhimurium. The DNA oligos used for tufB 
ampification, and for sequencing both tuf genes have been described 
previously [1 I]. Asymmetric PCR products were purified using a Ge- 
neClean kit and sequenced by the dideoxy method using T7 DNA 
polymerase (Pharmacia) and [a-35S]dATP. 
3. Results and discussion 
3.1. Mutant isolation and identification 
We have isolated kirromycin resistant mutations in the tufA 
and tufB genes of S. typhimurium. By DNA sequencing we have 
identified twelve different kirromycin resistant mutations. We 
have also sequenced a previously characterized kirromycin re- 
sistant mutation in t&A of E. coli, tufAa [15], and identified it 
as a novel mutation. These thirteen mutations map in eight 
different codons, in seven of which a single amino acid substi- 
tution results, while in one case a single amino acid is deleted. 
Four tuf mutations causing kirromycin resistance have been 
identified in E. coli [9,12]. We have isolated three of these 
mutations also in S. typhimurium, while the fourth one affects 
residue 124 where we have isolated two different mutations. All 
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fourteen mutations are listed in Table 1, where we give the 
amino acid residue numbers in E. coli and S. typhimurium 
(identical residues) and in Thermus aquaticus (contains three 
small insertions relative to E. coli) to facilitate comparison of 
the GDP and GTP structural forms of EF-Tu [4]. Throughout 
this report we use the E. coli numbering in the text and in the 
figures for simplicity. Residues 120, 124 and 160 are in domain 
I of EF-Tu, while residues 3 16, 329, 375 and 378 are in domain 
III. The amino acid deleted (residue 298) is in the loop connect- 
ing domains II and III. Each of these mutant forms of EF-Tu 
can individually support bacterial viability. No similar viable 
kirromycin resistant mutations have been isolated in domain II. 
Those mutations giving rise to kirromycin resistance that have 
been isolated in domain II are all individually inviable and 
essentially serve to expose the phenotype of a viable kirromycin 
resistance mutation on the other tufgene [ 11,161, although they 
may be at least partially active in the functions of EF-Tu 
[l&18]. Kirromycin has been crosslinked by borohydride re- 
duction to residue LYS~~’ in domain III of E. coli EF-Tu [19]. 
3.2. Location of kirromycin resistance mutations on the 30 
structures of EF-Tu 
We have mapped each of the residues where a substitution 
causes kirromycin resistance (and the crosslinked residue) onto 
the EF-Tu.GDP structure from E. coli [3] and onto the EF- 
Tu.GTP structure from Thermus aquaticus [4]. The 
results are shown in Fig. 1A and B. In this figure, the orienta- 
tion of the guanine nucleotide binding domain I is kept con- 
stant, while the relative orientation of domains II and III 
changes considerably depending on the nature of the bound 
nucleotide, as discussed by Kjeldgaard et al. [4]. In the GTP 
form (Fig. 1B) the seven residues where substitutions cause 
resistance to kirromycin cluster in the interface between do- 
mains I and III. In contrast, in the GDP form (Fig. 1A) the 
seven residues are widely dispersed, the three domain I muta- 
tions being still in the interface, while the domain III mutations 
are turned away because of the altered orientation of the do- 
mains. We suggest hat the most parsimonious interpretation 
Table 1 
Mutations in EF-Tu causing resistance to kirromycin 
Mutant position aa change nt change 
E.c., St. T.a. 
120 121 L, Leu+Gln CTG+CAG 
124 125 Q, Gln -+ Arg CAG -+ CGG 
Q, Gln + Glu CAG+GiiG 
Q. Gln -+ Lys* CAG -+xAG 
160 161 Y, Tyr+Asn TAC-+fiC 
Y, Tyr -+Asp TAC +EAC 
Y, Tyr -_) Cys TAC +T@ 
298 310 I, A lle A ATT 
316 328 G, Gly+Asp CGC+GAC 
329 341 Q, Gln + His CAG+C% 
375 387 A, Ala--f Thr GCA -_) ACX 
A, Ala + Ser GCA +TCA 
A, Ala 4 Val GCA +ETA 
378 390 E, Glu --) Lys* GAA +_@A 
E.c., St. and T.a. refer to amino acid residue numbers in Escheria coli, 
Salmonella typhimurium and Thermus aquaticus respectively. *These 
mutations have so far only been isolated in E. co/i. The mutation 
Gln124Lys was isolated and identified by Zeef and Bosch [12], the 
mutation- tufAa was isolated by Tapio and Isaksson [15] and the se- 
quence change Glu378Lys identified by us. 
of these locations on the structure is that kirromycin binds in 
vivo to the interface of domains I and III of EF-Tu.GTP 
According to this interpretation the mutations in the domain 
interface would cause resistance by interfering with the binding 
of kirromycin. The amino acid deletion in the loop linking 
domains II and III may cause resistance indirectly, by modify- 
ing the conformation of the proposed binding site in the inter- 
face between domain I and III. The crosslinking of kirromycin 
to Lys 3J7 in the E. coli EF-Tu is interesting. This lysine residue 
(Thr in Thermus aquaticus) is in the domain I-III interface in 
the EF-Tu.GDP conformation, but not in the EF-Tu.GTP 
conformation (Fig. 1A and B). This is compatible with kirro- 
mycin occupying the domain I-III interface in the EF-Tu . GDP 
form also, bringing Lys357 into the immediate neighbourhood 
of kirromycin. Kirromycin binds to both forms of EF-Tu in 
vitro [6], causing a hybrid conformation with characteristics of 
both GDP and GTP conformations [20,21]. Our data would 
suggest hat the interaction of kirromycin with EF-Tu need not 
neccessarily depend on specific interactions with residues on 
domain III as these would differ in the two forms of EF-Tu. 
This suggests the possibility that some of the domain I residues 
(124, 120 and 160), or residues in their immediate structural 
neighbourhood, may be directly involved in binding kirromycin 
to EF-Tu. Note that the size of the kirromycin molecule (MW 
797, Fig. 2) is such that it could, in elongated form, easily cover 
the length of the interface from TyrlM to Glnlz4. Studies of the 
complex of kirromycin and EF-Tu suggest hat two regions of 
the antibiotic, the chromophore N(lw(13) and the alkene 
region C(lQ-C(24), are involved in binding [22-241. 
3.3. Local structural consequences of the kirromycin resistance 
mutations in EF-Tu. GTP 
The three amino acid residues giving rise to kirromycin resis- 
tance mutations in domain I, Tyr’@‘, Leu’*’ and Glnlz4, are 
immediate neighbours in the 3D structure (Figs. lA, lB, 3A) 
and have side chains pointing in the same direction towards 
domain III. Tyr ‘60 has van der Waals interactions with Leu”’ 
and also hydrogen bonds with Arg’16 and with Glu315 in domain 
III (Fig. 3A and B). The mutations of Tyr160 to Asn, Asp and 
Cys (all of which have smaller side chains than Tyr) are each 
likely to result in the loss of these hydrogen bonds. Leu’*’ (Fig. 
3A) makes van der Waals interactions with Tyr160 and has a 
hydrophobic interaction with Leu3” in domain III. The muta- 
tion Leu’20-_)Gln can be expected to replace this hydrophobic 
interaction with a hydrogen bond interaction to another polar 
side chain in the interface. Gln’24 (Fig. 3A,C,D) hydrogen 
bonds to the main chain of Ala375 in domain III (note that Ala375 
is one of the mutant sites on domain III). Of the three mutations 
isolated at this position, Gln’24 to Arg, Glu and Lys, the Arg 
and Lys mutants may have polar interactions with other groups 
in the interface. 
There are four residues in domain III where substitutions 
were isolated, Gly316, Gln329 Ala375 and Glu3’*. The mutation 
Gl~“~-+Asp is likely to create a hydrogen bond to Tyr160 and 
possibly also a salt bridge to Arg”‘, both in domain I. The local 
consequences of the mutation Gln329+His are more difficult 
to predict. This residue is probably hydrogen bonded to Asp336 
and Thti3’ and these interactions may be maintained in the His 
mutant. Ala375 is hydrogen bonded through its main chain to 
Gln’24 in domain I. Two of the mutations at this position, Ala375 
to Thr and Ser, may form hydrogen bonds to the side chain of 
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Fig. 1. (A) Structure of EF-Tu.GDP from E. coli [3] and (B) EF-Tu in its GTP conformation from Thermus aquaticus [4] showing the positions and 
side chains of amino acids where mutations causing resistance to kirromycin have been isolated, and the site, 357, of borohydride crosslinking to 
kirromycin [19]. Note that all residues are numbered according to E. coli EF-Tu. 
Glnlz4. The third mutant, Ala3” + Val, may make hydrophobic 
interactions with Leu”‘. G1u3’* makes a salt bridge to Arg3’* 
will cause the loss of this salt bridge and of the hydrogen 
and a hydrogen bond with Tyr326. The mutation Gl~~‘~+Lys 
bonding interaction. Thus, the overall conclusion is that many 
of the amino acid substitutions causing kirromycin resistance 
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Fig. 2. Chemical structure of kirromycin. MW 797. 
Fig. 3. Residues in the interface of domains I and III of EF-Tu in the GTP conformation. Note that all residues are numbered according to E. coli 
EF-Tu. (A) Overview of residues Yl60, Ll20 and 4124, (B) Yl60 hydrogen bonding, (C) Q124 neighbourhood, (D) A375 neighbourhood. 
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may affect the strength of the interactions between domains I 
and III of EF-Tu. 
3.4. Secondary phenotypes 
Most of the kirromycin resistant substitution mutations also 
have secondary phenotypes, which probably reflects the ex- 
treme conservation and functional complexity of EF-Tu and its 
interactions. Increased translational errors, defective interac- 
tions with aminoacyl-tRNA or with the ribosome are some of 
the phenotypes associated with some of the previously de- 
scribed substitutions at positions 375 and 378 [25-271. Note that 
the affinity of EF-Tu for aminoacyl-tRNA is also drastically 
reduced by kirromycin binding [21]. We are currently investi- 
gating the secondary phenotypes associated with several of the 
new kirromycin resistant mutants described in this report. 
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